JPH08507763A - ボルデテラからの細胞結合蛋白質の抽出 - Google Patents
ボルデテラからの細胞結合蛋白質の抽出Info
- Publication number
- JPH08507763A JPH08507763A JP6519550A JP51955094A JPH08507763A JP H08507763 A JPH08507763 A JP H08507763A JP 6519550 A JP6519550 A JP 6519550A JP 51955094 A JP51955094 A JP 51955094A JP H08507763 A JPH08507763 A JP H08507763A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cell
- pertussis
- proteins
- flocculating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000588807 Bordetella Species 0.000 title claims description 4
- 238000000605 extraction Methods 0.000 title description 13
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 75
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 46
- 238000010438 heat treatment Methods 0.000 claims abstract description 20
- 239000008394 flocculating agent Substances 0.000 claims abstract description 17
- 239000000725 suspension Substances 0.000 claims abstract description 13
- 230000001580 bacterial effect Effects 0.000 claims abstract description 5
- 241000588832 Bordetella pertussis Species 0.000 claims description 35
- 239000006228 supernatant Substances 0.000 claims description 19
- 101710116435 Outer membrane protein Proteins 0.000 claims description 13
- 229960005486 vaccine Drugs 0.000 claims description 12
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical group [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 claims description 11
- 229910001626 barium chloride Inorganic materials 0.000 claims description 11
- 150000001768 cations Chemical class 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 229910052788 barium Inorganic materials 0.000 claims description 6
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical group [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 108010071023 Bacterial Outer Membrane Proteins Proteins 0.000 claims description 3
- 241000589968 Borrelia Species 0.000 claims description 3
- 241000606790 Haemophilus Species 0.000 claims description 3
- 108010052285 Membrane Proteins Proteins 0.000 claims description 3
- 102000018697 Membrane Proteins Human genes 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 150000004820 halides Chemical group 0.000 claims 1
- 159000000008 strontium salts Chemical class 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 26
- 230000004151 fermentation Effects 0.000 description 18
- 238000000855 fermentation Methods 0.000 description 17
- 108010081690 Pertussis Toxin Proteins 0.000 description 16
- 238000005189 flocculation Methods 0.000 description 16
- 230000016615 flocculation Effects 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 238000001262 western blot Methods 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 201000005702 Pertussis Diseases 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- -1 halide salts Chemical class 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 229960000074 biopharmaceutical Drugs 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 102000030621 adenylate cyclase Human genes 0.000 description 4
- 108060000200 adenylate cyclase Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000011031 large-scale manufacturing process Methods 0.000 description 4
- 229940066827 pertussis vaccine Drugs 0.000 description 4
- 229910052712 strontium Chemical class 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 108010021711 pertactin Proteins 0.000 description 3
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical class [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FBOUIAKEJMZPQG-AWNIVKPZSA-N (1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol Chemical compound C1=NC=NN1/C(C(O)C(C)(C)C)=C/C1=CC=C(Cl)C=C1Cl FBOUIAKEJMZPQG-AWNIVKPZSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000588779 Bordetella bronchiseptica Species 0.000 description 2
- 241000917014 Bordetella pertussis 18323 Species 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229910001631 strontium chloride Inorganic materials 0.000 description 2
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- 241000588780 Bordetella parapertussis Species 0.000 description 1
- 241000280604 Bordetella pertussis CS Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000644323 Escherichia coli C Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- DMGNFLJBACZMRM-UHFFFAOYSA-N O[P] Chemical compound O[P] DMGNFLJBACZMRM-UHFFFAOYSA-N 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Catalysts (AREA)
- Saccharide Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.加熱処理によって宿主細胞から蛋白質を放出させることからなる細菌原の 細胞結合した外層膜蛋白質の強化された単離方法であって、該細胞結合した蛋白 質の懸濁液を加熱処理前にフロキュレート化剤と接触させることを特徴とする蛋 白質の強化された単離方法。 2.細胞結合した蛋白質がボルデテラ、ヘモフィルス、エシュリキア、ストレ プトコッカスまたはボレリア種の外層膜蛋白質である請求項1記載の方法。 3.外層膜蛋白質がボルデテラ・ペルツッシスの69kD蛋白質である請求項 2記載の方法。 4.フロキュレート化剤が二価カチオンを含む物質である請求項1〜3記載の いずれか1つの方法。 5.フロキュレート化剤がバリウム、カルシウムまたはストロンチウム塩であ る請求項4記載の方法。 6.塩がハライドである請求項5記載の方法。 7.塩が塩化物である請求項6記載の方法。 8.塩が塩化バリウムである請求項7記載の方法。 9.細胞結合した蛋白質をpHが4〜10の範囲にある上清に懸濁させる請求 項1〜8記載のいずれか1つの方法。 10.細胞結合した細菌原の外層膜蛋白質からなる無細胞ワクチンであって、 該蛋白質が、宿主細胞の懸濁液をフロキュレート化剤と接触させ、つづいて加熱 処理に付すことにより該宿主細胞より放出されることを特徴とする無細胞ワクチ ン。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939304399A GB9304399D0 (en) | 1993-03-04 | 1993-03-04 | Novel process |
GB9304399.0 | 1993-03-04 | ||
PCT/EP1994/000597 WO1994020538A1 (en) | 1993-03-04 | 1994-02-28 | Extraction of cell-bound protein from bordetella |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08507763A true JPH08507763A (ja) | 1996-08-20 |
JP3629555B2 JP3629555B2 (ja) | 2005-03-16 |
Family
ID=10731444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51955094A Expired - Lifetime JP3629555B2 (ja) | 1993-03-04 | 1994-02-28 | ボルデテラからの細胞結合蛋白質の抽出 |
Country Status (17)
Country | Link |
---|---|
US (1) | US6106842A (ja) |
EP (1) | EP0687271B1 (ja) |
JP (1) | JP3629555B2 (ja) |
KR (1) | KR100290059B1 (ja) |
CN (1) | CN1055702C (ja) |
AT (1) | ATE172207T1 (ja) |
AU (1) | AU673587B2 (ja) |
CA (1) | CA2157375C (ja) |
DE (1) | DE69413952T2 (ja) |
DK (1) | DK0687271T3 (ja) |
ES (1) | ES2125442T3 (ja) |
GB (1) | GB9304399D0 (ja) |
HK (1) | HK1012404A1 (ja) |
NZ (1) | NZ262724A (ja) |
TW (1) | TW390888B (ja) |
WO (1) | WO1994020538A1 (ja) |
ZA (1) | ZA941448B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020529989A (ja) * | 2017-08-01 | 2020-10-15 | グリーン・クロス・コーポレイションGreen Cross Corp. | 凍結および解凍プロセスを含むボルデテラ・パータシス(bordetella pertussis)由来タンパク質を得る方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6444211B2 (en) * | 1991-04-03 | 2002-09-03 | Connaught Laboratories, Inc. | Purification of a pertussis outer membrane protein |
GB9205704D0 (en) * | 1992-03-16 | 1992-04-29 | Connaught Lab | High molecular weight membrane proteins of non-typeable haemophilus |
US20040126853A1 (en) * | 2002-06-20 | 2004-07-01 | Novozymes A/S | Flocculation with divalent salt |
WO2010131111A1 (en) * | 2009-05-11 | 2010-11-18 | Novartis Ag | Antigen purification process for pertactin antigen |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3405218A (en) * | 1965-09-22 | 1968-10-08 | Parke Davis & Co | Extracting bordetella pertussis antigens with lithium bromide |
US3465078A (en) * | 1965-10-21 | 1969-09-02 | Sydney Z Spiesel | Method of recovering antigens from bordetella pertussis cells |
US3862109A (en) * | 1968-10-12 | 1975-01-21 | Hitachi Ltd | Method for obtaining a protein isolate from hydrocarbon assimilating microbial cells |
US4464474A (en) * | 1980-07-09 | 1984-08-07 | Connaught Laboratories Limited | Non-A, non-B hepatitis assay and vaccine |
GB8412207D0 (en) * | 1984-05-12 | 1984-06-20 | Wellcome Found | Antigenic preparations |
US5101014A (en) * | 1989-02-10 | 1992-03-31 | United States Of America | Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis |
US5276142A (en) * | 1989-12-11 | 1994-01-04 | American Cyanamid Company | Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis |
US4988798A (en) * | 1990-01-22 | 1991-01-29 | Pitman-Moore, Inc. | Method for recovering recombinant proteins |
GB9007657D0 (en) * | 1990-04-04 | 1990-05-30 | Connaught Lab | Purification of a pertussis outer membrane protein(omp69) |
-
1993
- 1993-03-04 GB GB939304399A patent/GB9304399D0/en active Pending
-
1994
- 1994-02-28 ES ES94909902T patent/ES2125442T3/es not_active Expired - Lifetime
- 1994-02-28 WO PCT/EP1994/000597 patent/WO1994020538A1/en active IP Right Grant
- 1994-02-28 NZ NZ262724A patent/NZ262724A/en not_active IP Right Cessation
- 1994-02-28 EP EP94909902A patent/EP0687271B1/en not_active Expired - Lifetime
- 1994-02-28 JP JP51955094A patent/JP3629555B2/ja not_active Expired - Lifetime
- 1994-02-28 DE DE69413952T patent/DE69413952T2/de not_active Expired - Lifetime
- 1994-02-28 CA CA002157375A patent/CA2157375C/en not_active Expired - Lifetime
- 1994-02-28 AU AU62571/94A patent/AU673587B2/en not_active Expired
- 1994-02-28 DK DK94909902T patent/DK0687271T3/da active
- 1994-02-28 US US08/513,768 patent/US6106842A/en not_active Expired - Lifetime
- 1994-02-28 CN CN94191888A patent/CN1055702C/zh not_active Expired - Lifetime
- 1994-02-28 KR KR1019950703726A patent/KR100290059B1/ko not_active IP Right Cessation
- 1994-02-28 AT AT94909902T patent/ATE172207T1/de active
- 1994-03-02 ZA ZA941448A patent/ZA941448B/xx unknown
- 1994-04-19 TW TW083103480A patent/TW390888B/zh not_active IP Right Cessation
-
1998
- 1998-12-15 HK HK98113481A patent/HK1012404A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020529989A (ja) * | 2017-08-01 | 2020-10-15 | グリーン・クロス・コーポレイションGreen Cross Corp. | 凍結および解凍プロセスを含むボルデテラ・パータシス(bordetella pertussis)由来タンパク質を得る方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2157375A1 (en) | 1994-09-15 |
ZA941448B (en) | 1995-03-29 |
DE69413952T2 (de) | 1999-05-12 |
DK0687271T3 (da) | 1999-06-23 |
EP0687271B1 (en) | 1998-10-14 |
CA2157375C (en) | 2007-10-16 |
TW390888B (en) | 2000-05-21 |
GB9304399D0 (en) | 1993-04-21 |
HK1012404A1 (en) | 1999-07-30 |
CN1055702C (zh) | 2000-08-23 |
AU6257194A (en) | 1994-09-26 |
KR100290059B1 (ko) | 2001-05-15 |
ES2125442T3 (es) | 1999-03-01 |
AU673587B2 (en) | 1996-11-14 |
ATE172207T1 (de) | 1998-10-15 |
DE69413952D1 (de) | 1998-11-19 |
WO1994020538A1 (en) | 1994-09-15 |
CN1121724A (zh) | 1996-05-01 |
US6106842A (en) | 2000-08-22 |
KR960701095A (ko) | 1996-02-24 |
EP0687271A1 (en) | 1995-12-20 |
NZ262724A (en) | 1996-05-28 |
JP3629555B2 (ja) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU715417B2 (en) | Acellular pertussis vaccines and methods of preparation thereof | |
KR100242179B1 (ko) | 디스크 드라이브 데이타경로 보전 제어구조 | |
AU649950B2 (en) | A method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same | |
JP4589852B2 (ja) | 非細胞性百日咳ワクチンおよびその製造方法 | |
JP2841094B2 (ja) | 在郷軍人病ワクチン及びその製造方法 | |
EP0914153A1 (en) | Multivalent dtp-polio vaccines | |
US4374127A (en) | Herpes sub unit vaccine | |
JPS60246321A (ja) | 抗原性調製物および該調製物の単離法 | |
AU641711B2 (en) | Process for purification of a 69 000 dalton antigenetic protein from bordetella pertussis | |
EP0527753A1 (en) | CLEANING A PERTUSSIS EXTERIOR MEMBRANE PROTEIN. | |
JP2999480B2 (ja) | 百日咳感染及び毒性過程に対する保護抗原を得るための方法 | |
JP3629555B2 (ja) | ボルデテラからの細胞結合蛋白質の抽出 | |
HELTING et al. | SEROTYPE DETERMINANT PROTEIN OF NEISSERIA MENINGITIDIS: Large Scale Preparation by Direct Detergent Treatment of the Bacterial Cells | |
Frandsen et al. | Characterization of toxin from different strains of Pasteurella multocida serotype A and D | |
US6444211B2 (en) | Purification of a pertussis outer membrane protein | |
JPH05247099A (ja) | ウマのヘルペスウイルスに対するワクチンおよびそれらの調製 | |
KR810001317B1 (ko) | 혼합백신의 제조방법 | |
EP0141671A2 (en) | Bordetella bronchiseptica pilus subunit protein vaccine, composition of matter, and processes for their preparation | |
Sutherland | Studies on the Genus Bordetella. | |
FRANDSEN et al. | of zyxwvutsrqponmlk | |
US20010051163A1 (en) | Purification of a pertussis outer membrane protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040809 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20041102 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041122 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041116 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081224 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091224 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101224 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101224 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111224 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111224 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121224 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121224 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131224 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |